<DOC>
	<DOC>NCT01688050</DOC>
	<brief_summary>The TRANSFIX study is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® TX2® Low Profile Endovascular Graft for treatment of Blunt Thoracic Aortic Injury.</brief_summary>
	<brief_title>TRANSFIX Zenith® Transection Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Thoracic Injuries</mesh_term>
	<mesh_term>Wounds, Nonpenetrating</mesh_term>
	<criteria>Vessels suitable for endovascular access and stent graft placement Blunt thoracic aortic injury of the descending thoracic aorta At least 16 years of age Informed consent given by patient or legally authorized representative Clinical considerations that would compromise patient safety or study outcomes Unsuitable arterial anatomy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Blunt thoracic aortic injury</keyword>
	<keyword>Transection</keyword>
	<keyword>Endovascular graft</keyword>
</DOC>